Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhenium-188-SSS lipiodol
- Development stage
- Phase 1
- Lead developer
- Centre Eugene Marquis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intra-arterial, Transarterial (hepatic Artery Injection)
01
Overview
**Rhenium-188-SSS lipiodol** is an investigational radiopharmaceutical for transarterial radioembolisation therapy of hepatocellular carcinoma (HCC), especially in patients with advanced disease and portal vein thrombosis. The drug formulation consists of a stable rhenium-188 (a high energy beta-emitting radionuclide) complex that is highly soluble in Lipiodol—a radiopaque oil made from iodinated fatty acid ethyl esters derived from poppy seed oil. The mechanism of action relies on the selective uptake of Lipiodol by hepatocellular carcinoma lesions, where the rhenium-188 delivers localized beta radiation (\( \beta^- \)) to tumor cells, causing cytotoxic damage with minimal systemic exposure. Rhenium-188-SSS lipiodol offers improved in vivo stability and tumor targeting compared to earlier radiolabeled Lipiodol (such as rhenium-188-HDD lipiodol), with low urinary and fecal excretion. It is administered by intra-arterial injection into the hepatic artery for targeted radioembolization in non-resectable or non-transplantable liver cancer cases. Phase I clinical data indicate acceptable safety and encouraging response rates, and Phase II trials are underway[1][2][3].
- Brand names
- Lipiodol (carrier oil)
- Other names
- Rhenium-188 SSS LipiodolRhenium188 SSS LipiodolRhenium 188 SSS Lipiodol188Re-SSS LipiodolRhenium-188 SSS/Lipiodol
Beyond the preview
Go deeper on rhenium-188-SSS lipiodol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhenium-188-SSS lipiodol.